GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PT Jayamas Medica Industri Tbk (ISX:OMED) » Definitions » ROC %

PT Jayamas Medica Industri Tbk (ISX:OMED) ROC % : 18.51% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is PT Jayamas Medica Industri Tbk ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. PT Jayamas Medica Industri Tbk's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was 18.51%.

As of today (2024-05-24), PT Jayamas Medica Industri Tbk's WACC % is 10.34%. PT Jayamas Medica Industri Tbk's ROC % is 18.95% (calculated using TTM income statement data). PT Jayamas Medica Industri Tbk generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


PT Jayamas Medica Industri Tbk ROC % Historical Data

The historical data trend for PT Jayamas Medica Industri Tbk's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Jayamas Medica Industri Tbk ROC % Chart

PT Jayamas Medica Industri Tbk Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
70.23 171.58 102.55 36.19 21.38

PT Jayamas Medica Industri Tbk Quarterly Data
Dec19 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.71 17.16 19.07 20.50 18.51

PT Jayamas Medica Industri Tbk ROC % Calculation

PT Jayamas Medica Industri Tbk's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=300874.591 * ( 1 - 19.98% )/( (970142.614 + 1282072.982)/ 2 )
=240759.8477182/1126107.798
=21.38 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2507318.881 - 206627.41 - ( 1330548.857 - max(0, 230946.309 - 2112847.404+1330548.857))
=970142.614

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2581482.597 - 115191.579 - ( 1184218.036 - max(0, 136134.311 - 2047267.019+1184218.036))
=1282072.982

PT Jayamas Medica Industri Tbk's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=310178.316 * ( 1 - 22.03% )/( (1282072.982 + 1330732.036)/ 2 )
=241846.0329852/1306402.509
=18.51 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2581482.597 - 115191.579 - ( 1184218.036 - max(0, 136134.311 - 2047267.019+1184218.036))
=1282072.982

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2646510.813 - 121128.624 - ( 1194650.153 - max(0, 134463.795 - 2090470.174+1194650.153))
=1330732.036

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Jayamas Medica Industri Tbk  (ISX:OMED) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, PT Jayamas Medica Industri Tbk's WACC % is 10.34%. PT Jayamas Medica Industri Tbk's ROC % is 18.95% (calculated using TTM income statement data). PT Jayamas Medica Industri Tbk generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


PT Jayamas Medica Industri Tbk ROC % Related Terms

Thank you for viewing the detailed overview of PT Jayamas Medica Industri Tbk's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Jayamas Medica Industri Tbk (ISX:OMED) Business Description

Traded in Other Exchanges
N/A
Address
Sebelah Selatan Jalan By Pass RT 05 / RW 01, Kelurahan Sidomojo, Kecamatan Krian, Sidoarjo, Jawa Timur, East Java, IDN, 61262
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing medical devices and other household health supplies. It initially began with the manufacture of urine bags, OneMed later expanded in the manufacturing business of medical equipment and supplies in Indonesia with a range of variants of products manufactured locally. The Company and its Subsidiaries has three main divisions: Manufacturing; Distribution and Retail.

PT Jayamas Medica Industri Tbk (ISX:OMED) Headlines

From GuruFocus

OncoMed Provides Update on Navicixizumab Partnership

By Marketwired Marketwired 09-20-2018

OncoMed Announces Early Clinical Data for anti-TIGIT Antibody

By Marketwired Marketwired 11-09-2018